JACC in a Flash | ESC 2024 Science in JACC; Semaglutide Improving CV Outcomes; GUARD-AF; More
Featured topics and Editors' Picks from all of ACC's JACC Journals.
ESC Congress 2024 Science Published Across JACC Journals
Coinciding with research presented during ESC Congress 2024, 67 manuscripts including Late-Breaking Science, and 26 editorial comments and special communications were simultaneously published across nine of the JACC Journals. Read here some of the highlights. Click here to read all the manuscripts and to access all the related additional content, including conference video highlights with the authors, expert commentary from the editors, visual abstracts and more.
New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight Loss
Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19-related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC. The research was simultaneously published with presentations at the ESC Congress 2024.
Risk Score to Predict HF in Cancer Survivors?
A novel polygenic risk score for heart failure (PRS-HF) did not perform better than the Atherosclerosis Risk in Communities (ARIC-HF) risk score in predicting HF in a large population of patients with and without cancer, according to results from a study presented during ESC Congress 2024 and simultaneously published in JACC: CardioOncology.
GUARD-AF: Does Screening For Undiagnosed AFib Reduce Bleeding, Stroke Risk?
One-time screening for atrial fibrillation (AFib) using a 14-day, electrocardiographic (ECG) patch monitor in individuals aged ≥70 years did not reduce rates of bleeding or stroke, based on results from the GUARD-AF trial presented at ESC Congress 2024 and simultaneously published in JACC.
ASSURE DES: Continuing vs. Interrupting Aspirin Therapy Before Noncardiac Surgery in Patients With DES
Continuing aspirin monotherapy for patients with previous drug-eluting stents (DES) who are undergoing low-to-intermediate risk noncardiac surgery did not significantly reduce ischemic events compared with temporarily holding all antiplatelet therapy before the surgery, according to findings from the ASSURE DES trial presented at ESC Congress 2024 and simultaneously published in JACC.
FIRE: Similar Benefit With Complete Revascularization in STEMI, NSTEMI
The use of physiology-guided complete revascularization is superior to a culprit-only strategy for older patients with either STEMI or NSTEMI, according to a prespecified substudy of the FIRE trial presented as a Late-Breaking Clinical Trial at ESC 2024 and simultaneously published in JACC.
Expert Analysis on TOP TRIALS FROM ESC Congress 2024
Join Valentin Fuster, MD, PhD, MACC, and expert panelists Christine Albert, MD, MPH, FACC; Gry Dahle, MD, PhD; James L. Januzzi Jr., MD, FACC; and Anna Petronio, MD, in a dynamic discussion on the most impactful trials from ESC Congress 2024. In this installment of ACC Cardiology Hour, they discuss key takeaways and implications of HELIOS-B, OCEANIC-AF, EPIC-CAD, ABYSS, Culprit vs. Complete, NOTION-3, RESHAPE-HF2, MATTERHORN and SELECT-COVID-19. Watch the full video and jump to individual trial discussions at JACC.org/CardiologyHour.
Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Cardiovascular Care Team, COVID-19 Hub, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Stable Ischemic Heart Disease, Atherosclerotic Disease (CAD/PAD), Anticoagulation Management and Atrial Fibrillation, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Interventions and Coronary Artery Disease, Interventions and Vascular Medicine, Chronic Angina
Keywords: Cardiology Magazine, ACC Publications, ESC Congress, ESC24, Communication, Weight Loss, COVID-19, Heart Failure, Obesity, Atrial Fibrillation, Electrocardiography, Anticoagulants, Primary Health Care, Stroke, Stroke Volume, Hemorrhage, Drug-Eluting Stents, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention, Aspirin, Non-ST Elevated Myocardial Infarction, ST Elevation Myocardial Infarction, Coronary Artery Disease, Shock, Cardiogenic, Myocardial Infarction, Hypotension, Cardio-oncology, Polymorphism, Single Nucleotide, Cancer Survivors
